Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Grabenstein

Showing results (91-100 of 167) with videos related to

Pageof 17
Sort By:
Vaccine|May 1, 2012
Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adultsJohn D Grabenstein, Susan B Manoff
Experimental and Molecular Pathology|May 19, 2000
Re: Antibodies to squalene in Gulf War SyndromeC R Alving, J D Grabenstein
Hospital Pharmacy|November 1, 1991
Interviewing and counseling patients about immunizationsJ K Kirk, J D Grabenstein
The Journal of the Kentucky Medical Association|January 15, 2002
What I need to know about anthrax todayR D Harris, J D Grabenstein
The Annals of Pharmacotherapy|December 7, 2006
Screening adults for multiple immunization needsJohn D Grabenstein, Ralph R Watson
Drug Intelligence & Clinical Pharmacy|April 1, 1988
Screening adults for multiple immunization needsJ D Grabenstein, R R Watson
Annals of Allergy|September 1, 1989
Incidence of anaphylactic self-treatment in an outpatient populationJ D Grabenstein, L J Smith
Travel Medicine and Infectious Disease|June 12, 2023
Global geotemporal distribution of chikungunya disease, 2011-2022John D Grabenstein, Aditya Singh Tomar
Military Medicine|March 21, 2002
Ambulatory medical visits among anthrax-vaccinated and unvaccinated personnel after return from southwest AsiaPaul A Rehme, Robert Williams, John Grabenstein
Vaccine|November 17, 2012
Cost-effectiveness of adult pneumococcal vaccination: responding to: Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years. Vaccine 2012;30(August (36)):5437-44John D Grabenstein, Megan A O'Brien, Jieling Chen
Pageof 17

Showing results (91-100 of 167) with videos related to

Sort By:
Pageof 17
Vaccine|May 1, 2012
Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adultsJohn D Grabenstein, Susan B Manoff
Experimental and Molecular Pathology|May 19, 2000
Re: Antibodies to squalene in Gulf War SyndromeC R Alving, J D Grabenstein
Hospital Pharmacy|November 1, 1991
Interviewing and counseling patients about immunizationsJ K Kirk, J D Grabenstein
The Journal of the Kentucky Medical Association|January 15, 2002
What I need to know about anthrax todayR D Harris, J D Grabenstein
The Annals of Pharmacotherapy|December 7, 2006
Screening adults for multiple immunization needsJohn D Grabenstein, Ralph R Watson
Drug Intelligence & Clinical Pharmacy|April 1, 1988
Screening adults for multiple immunization needsJ D Grabenstein, R R Watson
Annals of Allergy|September 1, 1989
Incidence of anaphylactic self-treatment in an outpatient populationJ D Grabenstein, L J Smith
Travel Medicine and Infectious Disease|June 12, 2023
Global geotemporal distribution of chikungunya disease, 2011-2022John D Grabenstein, Aditya Singh Tomar
Military Medicine|March 21, 2002
Ambulatory medical visits among anthrax-vaccinated and unvaccinated personnel after return from southwest AsiaPaul A Rehme, Robert Williams, John Grabenstein
Vaccine|November 17, 2012
Cost-effectiveness of adult pneumococcal vaccination: responding to: Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years. Vaccine 2012;30(August (36)):5437-44John D Grabenstein, Megan A O'Brien, Jieling Chen
Pageof 17